Key result
Pentamidine at near therapeutic concentrations disrupts normal KCNH2 channel protein processing and maturation, reducing its surface membrane expression as a novel mechanism for drug-induced LQTS.
Answers are grounded in this paper and cite their sources.
Highlights a novel mechanism for drug-induced long QT syndrome where pentamidine disrupts KCNH2 channel protein trafficking rather than directly blocking the channel.
Drug induced long QT syndrome (LQTS) can lead to cardiac arrhythmias and sudden death, and has emerged as a worldwide problem. Most drugs that cause this are thought to directly block a specific cardiac ion channel (KCNH2 or hERG) that carries the rapidly activating delayed rectifier potassium current, I(Kr). In this issue of the British Journal of Pharmacology, evidence is presented to support a new mechanism for causing drug induced LQTS. The drug pentamidine, at near therapeutic concentrations that do not cause direct KCNH2 channel block, disrupts normal KCNH2 channel protein processing and maturation to reduce its surface membrane expression. This indirect mechanism for reducing I(Kr) is novel, and whether other drugs may cause similar protein trafficking abnormalities is largely unknown.
No takes yet. Share an insight, caveat, or question.
Eckhardt et al. (2005) conducted an editorial in Drug-induced long QT syndrome (LQTS). Pentamidine was evaluated on KCNH2 channel protein processing and maturation. Pentamidine at near therapeutic concentrations disrupts normal KCNH2 channel protein processing and maturation, reducing its surface membrane expression as a novel mechanism for drug-induced LQTS.
Synapse has enriched 10 related papers. Consider them for comparative context: